Literature DB >> 24756548

Long-term quality of life after Ivor Lewis esophagectomy for esophageal cancer.

Silvio Däster1, Savas D Soysal, Lea Stoll, Ralph Peterli, Markus von Flüe, Christoph Ackermann.   

Abstract

BACKGROUND: Esophagectomy has a potentially high impact on physical, emotional, and social functions. The aim of this study was to assess long-term health-related quality of life (QOL) after esophageal cancer surgery.
METHODS: We analyzed all patients who underwent an Ivor Lewis esophagectomy for resectable esophageal cancer in our hospital from 1999 to 2010. QOL was assessed using the European Organization for Research and Treatment of Cancer general questionnaire QLQ-C30 and esophagus-specific questionnaire QLQ-OES18.
RESULTS: A total of 150 patients were operated in the surveyed 12-year period. At the time of analysis, 46 patients (31 %) were eligible for assessment, 97 patients (65 %) had died or experienced tumor recurrence, and seven patients (5 %) were lost to follow-up. Of the 46 eligible patients, 43 (94 %) returned the questionnaires. The median observation interval between the operation and QOL assessment was 40 (range 21-135) months. The QLQ-C30 mean score of global health status and general QOL was similar to that of a healthy reference population. Most of the QLQ-C30 mean scores of functional and symptom scales and QLQ-OES18 symptom scales showed a worse result than for a healthy reference population. The highest mean scores were reflux and eating problems.
CONCLUSIONS: In the long term, Ivor Lewis esophagectomy provides a generally good QOL for patients with esophageal cancer, which is comparable to a healthy reference population. However, some patients suffer from significant symptoms. Reflux and eating problems were the most relevant complaints. Dietary counseling is therefore important in the postoperative course.

Entities:  

Mesh:

Year:  2014        PMID: 24756548     DOI: 10.1007/s00268-014-2576-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  35 in total

1.  Health-related quality of life after Ivor Lewis esophagectomy.

Authors:  Christian A Gutschow; Arnulf H Hölscher; Jessica Leers; Hans Fuchs; Marc Bludau; Klaus L Prenzel; E Bollschweiler; Wolfgang Schröder
Journal:  Langenbecks Arch Surg       Date:  2012-06-04       Impact factor: 3.445

2.  Is botulinum toxin injection of the pylorus during Ivor Lewis [corrected] esophagogastrectomy the optimal drainage strategy?

Authors:  Robert James Cerfolio; Ayesha S Bryant; Cheri L Canon; Roopa Dhawan; Mohamad A Eloubeidi
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03       Impact factor: 5.209

3.  Defining a successful esophagectomy.

Authors:  Claire L Donohoe; John V Reynolds
Journal:  Ann Surg       Date:  2014-05       Impact factor: 12.969

4.  Carcinoma of the OEsophagus. Radical Resection with OEsophago-gastrostomy for a Midthoracic Growth by a Right Transpleural Approach.

Authors:  I Lewis
Journal:  Proc R Soc Med       Date:  1945-07

5.  A physical model of the intrathoracic stomach.

Authors:  W A Bemelman; J Verburg; W H Brummelkamp; P J Klopper
Journal:  Am J Physiol       Date:  1988-02

6.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

Authors:  Michael Stahl; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Martin K Walz; Siegfried Seeber; Bodo Klump; Wilfried Budach; Reinhard Teichmann; Marcus Schmitt; Gerd Schmitt; Claus Franke; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

7.  Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.

Authors:  Surya S A Y Biere; Mark I van Berge Henegouwen; Kirsten W Maas; Luigi Bonavina; Camiel Rosman; Josep Roig Garcia; Suzanne S Gisbertz; Jean H G Klinkenbijl; Markus W Hollmann; Elly S M de Lange; H Jaap Bonjer; Donald L van der Peet; Miguel A Cuesta
Journal:  Lancet       Date:  2012-05-01       Impact factor: 79.321

8.  Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. The EORTC Quality of Life Study Group.

Authors:  J M Blazeby; D Alderson; K Winstone; R Steyn; E Hammerlid; J Arraras; J R Farndon
Journal:  Eur J Cancer       Date:  1996-10       Impact factor: 9.162

9.  Quality of life during potentially curative treatment for locally advanced oesophageal cancer.

Authors:  K N L Avery; C Metcalfe; C P Barham; D Alderson; S J Falk; J M Blazeby
Journal:  Br J Surg       Date:  2007-11       Impact factor: 6.939

10.  The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer.

Authors:  M McKernan; D C McMillan; J R Anderson; W J Angerson; R C Stuart
Journal:  Br J Cancer       Date:  2008-02-12       Impact factor: 7.640

View more
  10 in total

1.  Physical decline and its implications in the management of oesophageal and gastric cancer: a systematic review.

Authors:  Linda O'Neill; Jonathan Moran; Emer M Guinan; John V Reynolds; Juliette Hussey
Journal:  J Cancer Surviv       Date:  2018-05-23       Impact factor: 4.442

2.  Health-Related Quality of Life Associated with Barrett's Esophagus and Cancer.

Authors:  Norma B Bulamu; Gang Chen; Julie Ratcliffe; Ann Schloite; Tim Bright; David I Watson
Journal:  World J Surg       Date:  2019-06       Impact factor: 3.352

3.  Long-term health-related quality of life following robot-assisted radical transmediastinal esophagectomy.

Authors:  Kotaro Sugawara; Shuntaro Yoshimura; Koichi Yagi; Masato Nishida; Susumu Aikou; Yukinori Yamagata; Kazuhiko Mori; Hiroharu Yamashita; Yasuyuki Seto
Journal:  Surg Endosc       Date:  2019-07-08       Impact factor: 4.584

4.  Continuously sutured versus linear-stapled anastomosis in robot-assisted hybrid Ivor Lewis esophageal surgery following neoadjuvant chemoradiotherapy: a single-center cohort study.

Authors:  Fiorenzo V Angehrn; Kerstin J Neuschütz; Daniel C Steinemann; Martin Bolli; Lana Fourie; Pauline Becker; Markus von Flüe
Journal:  Surg Endosc       Date:  2022-07-19       Impact factor: 3.453

5.  Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.

Authors:  Emer M Guinan; S L Doyle; A E Bennett; L O'Neill; J Gannon; J A Elliott; J O'Sullivan; J V Reynolds; J Hussey
Journal:  Support Care Cancer       Date:  2017-12-02       Impact factor: 3.603

6.  Comparison of Long-term Quality of Life in Patients with Esophageal Cancer after Ivor-Lewis, Mckeown, or Sweet Esophagectomy.

Authors:  Yu-Shang Yang; Qi-Xin Shang; Yong Yuan; Xiao-Ying Wu; Wei-Peng Hu; Long-Qi Chen
Journal:  J Gastrointest Surg       Date:  2018-10-08       Impact factor: 3.452

7.  Quality of life after esophageal resection.

Authors:  Wendy Jo Svetanoff; Rose McGahan; Saurabh Singhal; Carrie Bertellotti; Sumeet K Mittal
Journal:  Patient Relat Outcome Meas       Date:  2018-04-04

8.  Arterial Infusion Chemotherapy for Neoplastic Esophagogastric Anastomotic Strictures After Esophagectomy.

Authors:  Pengfei Xie; Meipan Yin; Wei He; Yaozhen Ma; Chunxia Li; Zhen Li; Xiaobing Li; Shuai Wang; Gang Wu
Journal:  Front Oncol       Date:  2021-05-26       Impact factor: 6.244

9.  Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis.

Authors:  Jacqueline N Chu; Jin Choi; Angela Tramontano; Christopher Morse; David Forcione; Norman S Nishioka; Julian A Abrams; Joel H Rubenstein; Chung Yin Kong; John M Inadomi; Chin Hur
Journal:  Clin Gastroenterol Hepatol       Date:  2017-11-24       Impact factor: 13.576

10.  From open Ivor Lewis esophagectomy to a hybrid robotic-assisted thoracoscopic approach: a single-center experience over two decades.

Authors:  Fiorenzo V Angehrn; Kerstin J Neuschütz; Lana Fourie; Alexander Wilhelm; Silvio Däster; Christoph Ackermann; Markus von Flüe; Daniel C Steinemann; Martin Bolli
Journal:  Langenbecks Arch Surg       Date:  2022-03-24       Impact factor: 2.895

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.